Edgewise Therapeutics, Inc. (NASDAQ:EWTX) to Post Q1 2025 Earnings of ($0.41) Per Share, Leerink Partnrs Forecasts

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Leerink Partnrs issued their Q1 2025 earnings per share estimates for Edgewise Therapeutics in a research report issued on Thursday, August 8th. Leerink Partnrs analyst J. Schwartz forecasts that the company will post earnings per share of ($0.41) for the quarter. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.59) per share. Leerink Partnrs also issued estimates for Edgewise Therapeutics’ Q4 2025 earnings at ($0.55) EPS.

Other analysts also recently issued reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $32.00 price target on shares of Edgewise Therapeutics in a research report on Thursday, July 25th. Truist Financial reiterated a “buy” rating and set a $25.00 target price on shares of Edgewise Therapeutics in a research note on Wednesday, April 17th. JPMorgan Chase & Co. increased their price target on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday. Wedbush reaffirmed an “outperform” rating and issued a $31.00 price objective on shares of Edgewise Therapeutics in a research report on Wednesday, June 26th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $48.00 target price on shares of Edgewise Therapeutics in a research note on Monday, July 1st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $33.40.

Edgewise Therapeutics Stock Up 0.2 %

Edgewise Therapeutics stock opened at $17.09 on Monday. Edgewise Therapeutics has a 52 week low of $5.12 and a 52 week high of $23.50. The company’s 50 day moving average price is $18.53 and its two-hundred day moving average price is $17.87. The stock has a market cap of $1.60 billion, a P/E ratio of -11.03 and a beta of 0.14.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.02.

Institutional Investors Weigh In On Edgewise Therapeutics

Large investors have recently added to or reduced their stakes in the company. RA Capital Management L.P. purchased a new stake in Edgewise Therapeutics during the first quarter valued at about $162,502,000. Baker BROS. Advisors LP boosted its holdings in Edgewise Therapeutics by 87.6% in the 1st quarter. Baker BROS. Advisors LP now owns 5,840,059 shares of the company’s stock worth $106,523,000 after buying an additional 2,727,273 shares during the period. Vanguard Group Inc. boosted its holdings in Edgewise Therapeutics by 89.0% in the 1st quarter. Vanguard Group Inc. now owns 4,017,433 shares of the company’s stock worth $73,278,000 after buying an additional 1,892,053 shares during the period. Frazier Life Sciences Management L.P. raised its holdings in Edgewise Therapeutics by 214.2% during the 4th quarter. Frazier Life Sciences Management L.P. now owns 2,667,203 shares of the company’s stock valued at $29,179,000 after acquiring an additional 1,818,181 shares during the period. Finally, Artal Group S.A. bought a new stake in Edgewise Therapeutics during the 1st quarter valued at $14,806,000.

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.